ReviewStem cells international2026
Adipose-Derived Stem Cell Exosomes in Diabetic Wound Repair: Molecular Crosstalk, Bioengineering Strategies, and Translational Challenges.
Review in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic wounds are sustained by persistent inflammation, impaired angiogenesis, abnormal extracellular matrix (ECM) remodeling, and delayed re-epithelialization. Adipose-derived stem cell exosomes (ADSC-Exos) offer a cell-free strategy because their multicomponent cargo can modulate immune responses, vascular regeneration, fibroblast activity, and epidermal repair. Mechanistic studies suggest that ADSC-Exos promote macrophage immunometabolic reprogramming, restore pro-angiogenic signaling, improve matrix homeostasis, and protect keratinocytes from oxidative injury. Engineering approaches and biomaterial-based delivery systems may further improve local retention, controlled release, and therapeutic activity. Distinct from existing ADSC-Exos reviews, this review adopts a pathology-to-translation framework that connects the major pathological features of diabetic wounds with ADSC-Exos mechanisms, engineering strategies, delivery optimization, and clinical translation. Particular emphasis is placed on donor- and process-dependent heterogeneity, potency assessment, GMP-compatible manufacturing, biodistribution, long-term safety, and regulation. Overall, ADSC-Exos represent a mechanistically compelling preclinical platform, but clinical translation will require reproducible product quality, standardized potency criteria, scalable manufacturing, and rigorous clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.